S&P 500   3,257.34 (-1.16%)
DOW   28,656.25 (-1.15%)
QQQ   219.09 (-1.62%)
AAPL   310.78 (-2.37%)
MSFT   163.15 (-1.15%)
GOOGL   1,434.66 (-2.15%)
AMZN   1,838.52 (-1.24%)
CGC   21.90 (-3.31%)
NVDA   241.33 (-3.66%)
BABA   207.29 (-3.02%)
MU   55.77 (-3.45%)
GE   11.54 (-1.54%)
TSLA   554.30 (-1.86%)
AMD   49.59 (-1.51%)
T   38.55 (+0.13%)
ACB   1.93 (-3.02%)
F   8.93 (-0.78%)
NFLX   344.87 (-2.35%)
BAC   33.11 (-1.31%)
DIS   136.96 (-2.23%)
GILD   63.71 (+0.89%)
S&P 500   3,257.34 (-1.16%)
DOW   28,656.25 (-1.15%)
QQQ   219.09 (-1.62%)
AAPL   310.78 (-2.37%)
MSFT   163.15 (-1.15%)
GOOGL   1,434.66 (-2.15%)
AMZN   1,838.52 (-1.24%)
CGC   21.90 (-3.31%)
NVDA   241.33 (-3.66%)
BABA   207.29 (-3.02%)
MU   55.77 (-3.45%)
GE   11.54 (-1.54%)
TSLA   554.30 (-1.86%)
AMD   49.59 (-1.51%)
T   38.55 (+0.13%)
ACB   1.93 (-3.02%)
F   8.93 (-0.78%)
NFLX   344.87 (-2.35%)
BAC   33.11 (-1.31%)
DIS   136.96 (-2.23%)
GILD   63.71 (+0.89%)
S&P 500   3,257.34 (-1.16%)
DOW   28,656.25 (-1.15%)
QQQ   219.09 (-1.62%)
AAPL   310.78 (-2.37%)
MSFT   163.15 (-1.15%)
GOOGL   1,434.66 (-2.15%)
AMZN   1,838.52 (-1.24%)
CGC   21.90 (-3.31%)
NVDA   241.33 (-3.66%)
BABA   207.29 (-3.02%)
MU   55.77 (-3.45%)
GE   11.54 (-1.54%)
TSLA   554.30 (-1.86%)
AMD   49.59 (-1.51%)
T   38.55 (+0.13%)
ACB   1.93 (-3.02%)
F   8.93 (-0.78%)
NFLX   344.87 (-2.35%)
BAC   33.11 (-1.31%)
DIS   136.96 (-2.23%)
GILD   63.71 (+0.89%)
S&P 500   3,257.34 (-1.16%)
DOW   28,656.25 (-1.15%)
QQQ   219.09 (-1.62%)
AAPL   310.78 (-2.37%)
MSFT   163.15 (-1.15%)
GOOGL   1,434.66 (-2.15%)
AMZN   1,838.52 (-1.24%)
CGC   21.90 (-3.31%)
NVDA   241.33 (-3.66%)
BABA   207.29 (-3.02%)
MU   55.77 (-3.45%)
GE   11.54 (-1.54%)
TSLA   554.30 (-1.86%)
AMD   49.59 (-1.51%)
T   38.55 (+0.13%)
ACB   1.93 (-3.02%)
F   8.93 (-0.78%)
NFLX   344.87 (-2.35%)
BAC   33.11 (-1.31%)
DIS   136.96 (-2.23%)
GILD   63.71 (+0.89%)
Log in

NASDAQ:BIOC - Biocept Stock Price, Forecast & News

$0.31
-0.01 (-3.13 %)
(As of 01/27/2020 12:43 PM ET)
Today's Range
$0.30
Now: $0.31
$0.32
50-Day Range
$0.24
MA: $0.31
$0.57
52-Week Range
$0.23
Now: $0.31
$2.50
Volume30,830 shs
Average Volume11.75 million shs
Market Capitalization$14.76 million
P/E RatioN/A
Dividend YieldN/A
Beta1.56
Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. Read More…

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BIOC
CUSIPN/A
Phone858-320-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.25 million
Book Value$0.66 per share

Profitability

Net Income$-24,570,000.00
Net Margins-552.54%

Miscellaneous

Employees95
Market Cap$14.76 million
Next Earnings Date3/26/2020 (Estimated)
OptionableOptionable

Receive BIOC News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOC and its competitors with MarketBeat's FREE daily newsletter.


Biocept (NASDAQ:BIOC) Frequently Asked Questions

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

How were Biocept's earnings last quarter?

Biocept Inc (NASDAQ:BIOC) announced its quarterly earnings data on Wednesday, November, 13th. The medical research company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.02. The medical research company earned $1.53 million during the quarter. Biocept had a negative net margin of 552.54% and a negative return on equity of 268.76%. View Biocept's Earnings History.

When is Biocept's next earnings date?

Biocept is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Biocept.

What price target have analysts set for BIOC?

1 analysts have issued twelve-month target prices for Biocept's shares. Their forecasts range from $1.00 to $1.00. On average, they anticipate Biocept's stock price to reach $1.00 in the next year. This suggests a possible upside of 222.6% from the stock's current price. View Analyst Price Targets for Biocept.

What is the consensus analysts' recommendation for Biocept?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biocept.

What are Wall Street analysts saying about Biocept stock?

Here are some recent quotes from research analysts about Biocept stock:
  • 1. Maxim Group analysts commented, "Biocept reported 1Q19 with ~$1M in revenue and a net loss of $5.9M. The company ended the period with $14.8M in cash on the balance sheet." (5/9/2019)
  • 2. According to Zacks Investment Research, "Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept, Inc. is headquartered in San Diego, California. " (2/13/2019)

Has Biocept been receiving favorable news coverage?

Headlines about BIOC stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Biocept earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Biocept.

Who are some of Biocept's key competitors?

What other stocks do shareholders of Biocept own?

Who are Biocept's key executives?

Biocept's management team includes the folowing people:
  • Mr. Michael W. Nall, CEO, Pres & Director (Age 56)
  • Mr. Timothy C. Kennedy, CFO, Sr. VP of Operations & Corp. Sec. (Age 61)
  • Dr. Lyle J. Arnold, Sr. VP of R&D, Chief Scientific Officer and Member of Scientific Advisory Board (Age 72)
  • Dr. Soon Kap Hahn Ph.D., Founder
  • Mr. Pavel Tsinberg, Director of Technology Devel.

How do I buy shares of Biocept?

Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Biocept's stock price today?

One share of BIOC stock can currently be purchased for approximately $0.31.

How big of a company is Biocept?

Biocept has a market capitalization of $14.76 million and generates $3.25 million in revenue each year. Biocept employs 95 workers across the globe.View Additional Information About Biocept.

What is Biocept's official website?

The official website for Biocept is http://www.biocept.com/.

How can I contact Biocept?

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected]


MarketBeat Community Rating for Biocept (NASDAQ BIOC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  296 (Vote Outperform)
Underperform Votes:  319 (Vote Underperform)
Total Votes:  615
MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote "Outperform" if you believe BIOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Featured Article: Bid-Ask Spread

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel